Anbio Biotechnology Class A (NNNN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Anbio Biotechnology Class A (NNNN) is down 66.8% since the beginning of the year. At $10 per share, NNNN is trading 81.9% below its 52-week high of $55.

Anbio Biotechnology Class A (NNNN) has returned -66.84% so far this year and -79.76% over the past 12 months.

Based on dividend-adjusted daily data since Feb 19, 2025, NNNN's average daily return is +0.55%, while the average monthly return is +17.96%. At this rate, an investment would double in approximately 0.3 years.

Historically, 61% of months were positive and 39% were negative. The best month was Jun 2025 with a return of +302.3%, while the worst month was Jun 2026 at -60.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 2 months.

On a daily basis, NNNN closed higher 51% of trading days. The best single day was Nov 5, 2025 with a return of +57.5%, while the worst single day was Oct 2, 2025 at -27.3%.

Anbio Biotechnology Class A has an annualized alpha of 273.75%, beta of 0.34, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 19, 2025.

• This stock captured 396.92% of S&P 500 Index gains and 185.18% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• Beta of 0.34 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NNNN ranks 13 for risk / return — in the bottom 13% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Anbio Biotechnology Class A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anbio Biotechnology Class A was 81.98%, occurring on Jul 10, 2026. The portfolio has not yet recovered.

The current Anbio Biotechnology Class A drawdown is 80.86%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Anbio Biotechnology Class A over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Anbio Biotechnology Class A is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.